United Therapeutics Corporation Reports 2016 Fourth Quarter And Annual Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
- AppLovin gains market share among e-commerce advertisers
United Therapeutics Corp. (UTHR) PT Raised to $175 at Oppenheimer
February 23, 2017 9:27 AM ESTOppenheimer raised its price target on United Therapeutics Corp. (NASDAQ: UTHR) to $175.00 (from $160.00) while maintaining a Outperform rating.
Analyst Hartaj Singh commented, "United Therapeutics (UTHR) reported 4Q16 sales/earnings and provided a business update to investors earlier today. The company reported a... More
United Therapeutics (UTHR) Tops Q4 EPS by 51c
February 22, 2017 6:01 AM ESTUnited Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $4.12, $0.51 better than the analyst estimate of $3.61. Revenue for the quarter came in at $409 million versus the consensus estimate of $415.51 million.
"Our annual 2016 financial results reflect continued growth as net revenues reached $1.6 billion and earnings exceeded $700... More
